Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Soluni
Boston, Massachusetts, United Statessoluni.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Solu Therapeutics is a clinical-stage biotechnology company pioneering bifunctional therapeutics that combine small molecules with monoclonal antibodies to target disease-driving cells. Its lead program, STX‑0712, is in Phase 1 trials for CMML. The CyTAC and TicTAC platforms enable targeting of cell surface proteins previously inaccessible to traditional antibodies. Early results focus on safety/tolerability and preliminary antitumor activity; further pipeline candidates are advancing rapidly toward development status.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Small moleculeMonoclonal antibodyBifunctional small molecule-antibody conjugate (CyTAC and TicTAC platforms)
- Industry
- Biotech
02
Partnerships
No major pharmaceutical partnerships publicly disclosed as of June 2025; open to collaborations around the CyTAC/TicTAC platforms.
Beyond the preview
Go deeper on Soluni.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Soluni.